Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Prognostic Significance of Re-Induction Necessity Based on Day-14 Residual Disease and Age-Adjusted Consolidation Approaches in Acute Myeloid Leukemia

  • By

  • Abiola Bolarinwa

  • Muhammad Yousuf

  • Aref Al-Kali

  • Hassan B. Alkhateeb

  • Abhishek A. Mangaonkar

  • Antoine N. Saliba

  • Mehrdad Hefazi Torghabeh

  • Aasiya Matin

  • Michelle A. Elliott

  • Mark R. Litzow

  • William J. Hogan

  • Mithun V. Shah

  • Mrinal M. Patnaik

  • Animesh Pardanani

  • Dong Chen

  • Kaaren K. Reichard

  • Rong He

  • Naseema Gangat

  • Ayalew Tefferi

  • Kebede H. Begna

  • September 30, 2026

Share

Objective:

To evaluate the effects of pre- and post-CR/CRi factors on ASCT-censored relapse-free survival (RFS), overall survival (OS), and survival after transplantation in patients receiving intensive induction chemotherapy for AML.

Approach:
  • Study Design: Retrospective study under IRB-approved protocols, analyzing patient data from 2004 to 2020.
  • Patient Cohort: 279 patients with AML, median age 58 years, receiving standard '7 + 3' induction therapy.
  • Data Analysis: Used standard statistical approaches to measure RFS and OS from the date CR/CRi was achieved.
Key Findings:
  • Median RFS was 18 months; 1-, 2-, and 3-year RFS rates were 63%, 42%, and 35%, respectively.
  • Median OS was 76 months, with a 5-year survival probability of 52%.
  • Re-induction was required for 27% of patients, leading to a median RFS of 14 months compared to 22 months for those not requiring it.
  • Age ≥65 years (HR 1.5, p = 0.047), post-CMN status (HR 1.7, p = 0.03), ELN adverse karyotype (HR 1.7, p < 0.01), and re-induction requirement (HR 1.9, p = 0.01) were independent predictors of relapse and OS.
Interpretation:

The necessity for re-induction is associated with poorer RFS and OS outcomes in AML patients, highlighting its prognostic significance.

Limitations:
  • Retrospective design may introduce bias.
  • Findings may not be generalizable to all AML populations.
Conclusion:

Re-induction necessity based on day-14 residual disease is a prognostic factor in AML, influencing both RFS and OS.

Original Source(s)

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

  • by Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A. Elliott, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Dong Chen, Kaaren K. Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H. Begna

  • September 30, 2026

Related Content

Nipple or skin-sparing mastectomy flap: can preoperative breast-MRI predict post-operative complications?

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

  • October 12, 2026

  • 9 min
Expanding surgical options for liver cancer and liver metastases

Advances in minimally invasive surgery and liver-directed therapies at UCI Health offer new treatment for complex liver malignancies.

  • October 14, 2026

  • 2 min